insights_auto
Why is DMYD-B down 4,80%?
Dive Deeperchevron_right
DMYD-B:STO
Diamyd Medical AB
SEKÂ 0,89
arrow_downward
-4,80%(-0,045) 1D
20 Nov., 17:29:38 GMT+1 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEKÂ 0,92
High
SEKÂ 0,94
Low
SEKÂ 0,89
Mkt. cap
135,12Â m.
Avg. vol.
501,53Â k
Volume
475,60Â k
52-wk high
SEKÂ 17,88
52-wk low
SEKÂ 0,86
EPS
-SEKÂ 1,76
Shares outstanding
134,00Â m.
No. of employees
42
Open
SEKÂ 0,92
High
SEKÂ 0,94
Low
SEKÂ 0,89
Mkt. cap
135,12Â m.
Avg. vol.
501,53Â k
Volume
475,60Â k
52-wk high
SEKÂ 17,88
52-wk low
SEKÂ 0,86
EPS
-SEKÂ 1,76
Shares outstanding
134,00Â m.
No. of employees
42
News stories
From web sources and news partners
Yahoo Finance
·
1 uur gelede
In the Last Tech Bust, the S&P 500 Lost Money for a Decade. History Says Stocks With the Highest Yields Gained 5.4% a Year.
24/7 Wall St.
·
3 uur gelede
The S&P 500 Is Now Below Every Wall Street Year-End Target for 2026
AP News
·
1 dag gelede
S&P 500 sinks 3.7% and Nasdaq composite goes negative for the year as tech sell-off worsens
Yahoo Finance
·
5 uur gelede
T-Bills Are Beating the Nasdaq, S&P 500 and Dow This Year
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB